Pictet Asset Management SA grew its position in Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE – Get Rating) by 91.6% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,890,502 shares of the biotechnology company’s stock after purchasing an additional 2,338,068 shares during the period. Pictet Asset Management SA owned about 7.99% of Aeglea BioTherapeutics worth $2,470,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds also recently made changes to their positions in the company. Suvretta Capital Management LLC raised its holdings in shares of Aeglea BioTherapeutics by 57.9% in the first quarter. Suvretta Capital Management LLC now owns 4,059,894 shares of the biotechnology company’s stock valued at $9,338,000 after purchasing an additional 1,488,894 shares during the last quarter. Nantahala Capital Management LLC increased its holdings in Aeglea BioTherapeutics by 13.8% during the first quarter. Nantahala Capital Management LLC now owns 3,200,593 shares of the biotechnology company’s stock worth $7,361,000 after buying an additional 387,033 shares during the last quarter. Rock Springs Capital Management LP increased its holdings in Aeglea BioTherapeutics by 14.8% during the first quarter. Rock Springs Capital Management LP now owns 1,811,425 shares of the biotechnology company’s stock worth $4,166,000 after buying an additional 234,129 shares during the last quarter. State Street Corp increased its holdings in Aeglea BioTherapeutics by 3.8% during the first quarter. State Street Corp now owns 787,048 shares of the biotechnology company’s stock worth $1,810,000 after buying an additional 29,007 shares during the last quarter. Finally, Ghost Tree Capital LLC purchased a new stake in Aeglea BioTherapeutics during the first quarter worth about $1,579,000. Hedge funds and other institutional investors own 81.03% of the company’s stock.
Aeglea BioTherapeutics Stock Up 4.1 %
Shares of NASDAQ:AGLE opened at $1.26 on Tuesday. The firm has a market capitalization of $77.50 million, a PE ratio of -1.11 and a beta of 1.91. Aeglea BioTherapeutics, Inc. has a twelve month low of $0.37 and a twelve month high of $7.09. The company has a 50-day moving average price of $0.74 and a two-hundred day moving average price of $0.74.
In other news, Director Marcio Souza acquired 90,000 shares of the business’s stock in a transaction dated Thursday, August 25th. The stock was bought at an average cost of $0.56 per share, for a total transaction of $50,400.00. Following the completion of the transaction, the director now owns 90,000 shares of the company’s stock, valued at $50,400. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 6.50% of the stock is owned by company insiders.
Wall Street Analysts Forecast Growth
AGLE has been the subject of a number of research analyst reports. Wells Fargo & Company upgraded shares of Aeglea BioTherapeutics from an “equal weight” rating to an “overweight” rating and raised their price objective for the stock from $1.50 to $2.00 in a report on Friday, October 28th. Jonestrading restated a “buy” rating and set a $3.00 price objective on shares of Aeglea BioTherapeutics in a report on Thursday, August 25th. StockNews.com began coverage on shares of Aeglea BioTherapeutics in a report on Wednesday, November 2nd. They set a “hold” rating for the company. Finally, Piper Sandler increased their target price on shares of Aeglea BioTherapeutics to $1.50 in a research report on Tuesday, November 1st. Three research analysts have rated the stock with a hold rating and three have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $1.88.
Aeglea BioTherapeutics Profile
Aeglea BioTherapeutics, Inc, a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency.
- Get a free copy of the StockNews.com research report on Aeglea BioTherapeutics (AGLE)
- Three Ways To Win The Online Gambling Industry
- Santa Claus Rally? Here’s What Needs to Happen
- Is Ardelyx is A Buy After Slip in Early 2022
- Will the Return of Bob Iger Return the Magic to Disney Stock?
- Is Tesla A Bargain Now As It Trades At Two-Year Lows?
Receive News & Ratings for Aeglea BioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea BioTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.